Businesses in the Israeli capital are benefitting from a massive increase in capacity on the IAG Cargo London Heathrow service. The additional capacity is the result of replacing narrowbody Airbus A321 aircraft with widebody Boeing 777 aircraft on 7 of the 14 weekly flights from London to Tel Aviv and on the return leg. The Boeing 777 has been operating on the route since 30th March 2014 and is set up to carry 18 tons on the Heathrow-Tel Aviv route and 16 tons on the Tel Aviv-Heathrow leg. As a result, IAG Cargo has increased capacity by 1000%. The additional capacity has been earmarked by the carrier to help target Tel Aviv’s high-growth pharmaceuticals market. Israel is a major manufacturing hub for pharmaceutical products and is seen as an important centre for the production of biopharma, due to low start-up costs and a large population of angel investors. Its burgeoning life sciences sector grew from 300 companies in 2003 to more than 900 in 2012, according to trade group Israel Advanced Technology IndustriesHYPERLINK "x-msg://67/#_ftn1"[1]. Alan Dorling, Global Head of Pharmaceuticals & Life Sciences at IAG Cargo commented: “Our industry-leading Constant Climate solution is perfect for keeping pharmaceuticals at the optimum temperature, which is essential for the biotech and pharmaceutical market. Combined with the additional capacity we have just brought onto the route, we can offer Israeli pharma businesses reliable, specialist lift options that can connect them to their markets around the world via our Heathrow hub.” IAG’s Constant Climate service ensures temperature sensitive shipments maintain a stable internal temperature regardless of changes in the ambient temperature. This solution supports temperatures from -20˚C to +25˚C and thereby protects the integrity and quality of pharmaceutical products.